BB Pureos Bioventures

Investment Focus

The venture capital company invests in private, innovative drug development companies primarily located in Switzerland, the European Union, the UK and in the United States. Pureos has a focus on companies developing the next generation of biological drugs (“biologics”). Pureos concentrates on indications with high medical need and conciders companies with programs in pre-clinical and early clinical stages and aims to stay invested during phases of highest value generation. Pureos aims to take significant stakes (10–20%) and looks to be actively involved at the board level of its portfolio companies. For further information please contact us under following address: Bellevue Asset Management AG Seestrasse 16 8700 Kusnacht/Zurich Tel. +41 (0)44 267 67 00 info@bellevue.ch